These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Nadri C; Dean B; Scarr E; Agam G Schizophr Res; 2004 Dec; 71(2-3):377-82. PubMed ID: 15474909 [TBL] [Abstract][Full Text] [Related]
3. Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia. Pandey GN; Rizavi HS; Tripathi M; Ren X Bipolar Disord; 2015 Mar; 17(2):160-71. PubMed ID: 25041379 [TBL] [Abstract][Full Text] [Related]
4. Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Kozlovsky N; Nadri C; Agam G Eur Neuropsychopharmacol; 2005 Jan; 15(1):1-11. PubMed ID: 15572268 [TBL] [Abstract][Full Text] [Related]
5. Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Blasi G; Napolitano F; Ursini G; Di Giorgio A; Caforio G; Taurisano P; Fazio L; Gelao B; Attrotto MT; Colagiorgio L; Todarello G; Piva F; Papazacharias A; Masellis R; Mancini M; Porcelli A; Romano R; Rampino A; Quarto T; Giulietti M; Lipska BK; Kleinman JE; Popolizio T; Weinberger DR; Usiello A; Bertolino A Am J Psychiatry; 2013 Aug; 170(8):868-76. PubMed ID: 23598903 [TBL] [Abstract][Full Text] [Related]
6. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Karege F; Perroud N; Burkhardt S; Schwald M; Ballmann E; La Harpe R; Malafosse A Biol Psychiatry; 2007 Jan; 61(2):240-5. PubMed ID: 16876135 [TBL] [Abstract][Full Text] [Related]
7. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Amar S; Shaltiel G; Mann L; Shamir A; Dean B; Scarr E; Bersudsky Y; Belmaker RH; Agam G Int J Neuropsychopharmacol; 2008 Mar; 11(2):197-205. PubMed ID: 17681085 [TBL] [Abstract][Full Text] [Related]
8. GSK-3 parameters in lymphocytes of schizophrenic patients. Nadri C; Kozlovsky N; Agam G; Bersudsky Y Psychiatry Res; 2002 Sep; 112(1):51-7. PubMed ID: 12379450 [TBL] [Abstract][Full Text] [Related]
9. Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3β and β-catenin. Ren X; Rizavi HS; Khan MA; Dwivedi Y; Pandey GN Int J Neuropsychopharmacol; 2013 Jun; 16(5):945-55. PubMed ID: 23110823 [TBL] [Abstract][Full Text] [Related]
10. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Kozlovsky N; Belmaker RH; Agam G Am J Psychiatry; 2000 May; 157(5):831-3. PubMed ID: 10784483 [TBL] [Abstract][Full Text] [Related]
11. Lack of effect of acute, subchronic, or chronic stress on glycogen synthase kinase-3beta protein levels in rat frontal cortex. Kozlovsky N; Belmaker RH; Agam G Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1309-12. PubMed ID: 12502018 [TBL] [Abstract][Full Text] [Related]
13. Low GSK-3 activity in frontal cortex of schizophrenic patients. Kozlovsky N; Belmaker RH; Agam G Schizophr Res; 2001 Oct; 52(1-2):101-5. PubMed ID: 11595396 [TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. Nadri C; Lipska BK; Kozlovsky N; Weinberger DR; Belmaker RH; Agam G Brain Res Dev Brain Res; 2003 Mar; 141(1-2):33-7. PubMed ID: 12644246 [TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Bersudsky Y; Shaldubina A; Kozlovsky N; Woodgett JR; Agam G; Belmaker RH Behav Pharmacol; 2008 May; 19(3):217-24. PubMed ID: 18469539 [TBL] [Abstract][Full Text] [Related]
16. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Zhao Z; Ksiezak-Reding H; Riggio S; Haroutunian V; Pasinetti GM Schizophr Res; 2006 May; 84(1):1-14. PubMed ID: 16581231 [TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Beasley C; Cotter D; Khan N; Pollard C; Sheppard P; Varndell I; Lovestone S; Anderton B; Everall I Neurosci Lett; 2001 Apr; 302(2-3):117-20. PubMed ID: 11290401 [TBL] [Abstract][Full Text] [Related]
18. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Beasley C; Cotter D; Everall I Schizophr Res; 2002 Nov; 58(1):63-7. PubMed ID: 12363391 [TBL] [Abstract][Full Text] [Related]
19. GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. Pandey GN; Dwivedi Y; Rizavi HS; Teppen T; Gaszner GL; Roberts RC; Conley RR Neurochem Res; 2009 Feb; 34(2):274-85. PubMed ID: 18584322 [TBL] [Abstract][Full Text] [Related]
20. GSK-3β Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia. Wang JR; Sun PH; Ren ZX; Meltzer HY; Zhen XC CNS Neurosci Ther; 2017 Feb; 23(2):174-187. PubMed ID: 27996211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]